Osteopontin: Its Potential Role in Cancer of Children and Young Adults

Karpinsky, Gabrielle; Fatyga, Aleksandra; Krawczyk, Małgorzata; Chamera, Madeleine; Sande, Natalia; Szmyd, Dagmara; Iżycka-Świeszewska, Ewa; Bień, Ewa

doi:10.2217/bmm-2016-0308

Cited by 18 publications

(18 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OPN gene is upregulated in primary central nervous system lymphomas (PCNSL) as compared to that in diffuse large B cell lymphoma (DLBCL) [208], and its levels in cerebrospinal fluid (CSF) appear to be an independent predictor of shorter progression-free and overall survival [209]. Serum levels of OPN also predict response to therapy and survival in DLBCL [210, 211] and serum and CSF levels were correlated to tumor bulk and response to therapy in children with acute lymphoblastic leukemia (ALL) [211]. Expression of OPN is increased in both bone marrow blasts and serum of patients with acute myeloid leukemia (AML), and high-OPN mRNA expression independently predicts overall survival ( p = 0.025), especially in low-intermediate risk forms [212].…”

Section: Osteopontin In Hematopoietic and Lymphoid Tumorsmentioning

confidence: 99%

Osteopontin at the Crossroads of Inflammation and Tumor Progression

Castello

Raineri

Salmi

et al. 2017

Mediators of Inflammation

139

132

View full text Add to dashboard Cite

Complex interactions between tumor and host cells regulate systemic tumor dissemination, a process that begins early at the primary tumor site and goes on until tumor cells detach themselves from the tumor mass and start migrating into the blood or lymphatic vessels. Metastatic cells colonize the target organs and are capable of surviving and growing at distant sites. In this context, osteopontin (OPN) appears to be a key determinant of the crosstalk between cancer cells and the host microenvironment, which in turn modulates immune evasion. OPN is overexpressed in several human carcinomas and has been implicated in inflammation, tumor progression, and metastasis. Thus, it represents one of the most attracting targets for cancer therapy. Within the tumor mass, OPN is secreted in various forms either by the tumor itself or by stroma cells, and it can exert either pro- or antitumorigenic effects according to the cell type and tumor microenvironment. Thus, targeting OPN for therapeutic purposes needs to take into account the heterogeneous functions of the multiple OPN forms with regard to cancer formation and progression. In this review, we will describe the role of systemic, tumor-derived, and stroma-derived OPN, highlighting its pivotal role at the crossroads of inflammation and tumor progression.

show abstract

Section: Osteopontin In Hematopoietic and Lymphoid Tumorsmentioning

confidence: 99%

Osteopontin at the Crossroads of Inflammation and Tumor Progression

Castello

Raineri

Salmi

et al. 2017

Mediators of Inflammation

139

132

View full text Add to dashboard Cite

show abstract

“…Here OPN in blood plasma might have a prognostic and predictive value on pediatric patients with traumatic brain injuries 21 . However, the potential of OPN as a biomarker in pediatric cancer patients is well accepted 22 …”

Section: Introductionmentioning

confidence: 99%

Plasma levels of osteopontin from birth to adulthood

Nourkami-Tutdibi

Graf

Beier

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Aim: Osteopontin (OPN) has been investigated as a biomarker for cancer and nonmalignant diseases during the last decades. Data about OPN as a potential biomarker in childhood diseases are still sparse, and reference values are not available in children. We aimed to establish reference values for children from birth to young adulthood and evaluate whether there are age-, gender-, and weight-specific differences. Method:Umbilical cord blood and blood plasma samples of 117 children were collected in the Children's Hospital of Saarland University in Homburg/Saar. OPN levels were measured by ELISA, and statistical analysis was performed using SPSS software.Results: Neonates, infants, toddlers, young children, adolescents, and adults were divided into the following six age groups: newborns (birth), infancy and toddlers (0-24 months), early childhood (3-6 years), middle childhood (7-11 years), adolescence (12-18 years), and adults (> 18 years).Highest blood OPN levels were found in the group of 0-1 years of age. OPN blood levels declined significantly with age (Spearman r = −0.874; P < 0.001). Conclusion:Our work is the first prospective and systematic study analyzing OPN cord blood and blood plasma levels in children of all ages. It is the first study yielding reference values for different age groups from birth to young adulthood. Our data give insight on how OPN in umbilical cord blood and OPN in blood plasma are physiologically influenced during childhood development and growth with high OPN levels after birth and a constant age-related decline until the age of 14, when OPN levels reach similar values to those measured in adults.

show abstract

“…High tumor OPN expression was reported to correlate with higher grade, stage and shorter relapse-free survival and overall survival in adult STS (Bache et al 2010 ). In pediatric cancers, the tumor expression of OPN was examined in leukemias, lymphomas, Langerhans cell histiocytosis, central nervous system (CNS) tumors, osteosarcoma and renal tumors (summarized by Karpinsky et al 2017 ). To date, there has been no study on the prognostic role of this marker in children with MPNST or other STS subtypes.…”

Section: Discussionmentioning

confidence: 99%

“…Our review of all publications on the role of OPN in cancers of children and young adults has shown that the monitoring of OPN protein level in serum and cerebral-spinal fluid of children with acute lyphoblastic anemia with CNS involvement and in patients with highly malignant brain tumors, reflected the tumor bulk and the response to CHT (Karpinsky et al 2017 ). To date, there have been no publications on the impact of OPN expression on response to naCHT in patients with STS.…”

Section: Discussionmentioning

confidence: 99%

Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor

Karpinsky

Krawczyk

Iżycka-Świeszewska

et al. 2018

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

PurposeSelected cell-cycle regulators and extracellular matrix proteins were found to play roles in malignant peripheral nerve sheath tumor (MPNST) biology. We aimed to analyze whether initial tumor tissue expressions of survivin, p53, cyclin D1, osteopontin (OPN) and fibronectin (FN) correlate with the response to neo-adjuvant CHT (naCHT) in children with advanced inoperable MPNST.MethodsThe study included 26 children with MPNST (M/F 14/12, median age 130 months) treated in Polish centers of pediatric oncology between 1992 and 2013. Tissue expression of markers was studied immunohistochemically in the manually performed tissue microarrays and assessed semi-quantitatively as low and high, based on the rate of positive cells and staining intensity.ResultsGood response to naCHT was noted in 47.6%, while poor—in 52.4% of patients. The response to naCHT was influenced negatively by the presence of neurofibromatosis NF1 and high initial tumor tissue expression of OPN, survivin, p53 and cyclin D1. Patients with high tumor expression of either OPN, survivin or p53 and those with simultaneous high expression of ≥ 3 of the markers, responded significantly worse to naCHT, than patients, in whom expression of ≤ 2 markers were detected at diagnosis. Nearly, 85% of patients expressing ≥ 3 markers, responded poor to CHT; while 87.5% of children, expressing ≤ 2 markers, were good responders.ConclusionThe initial tumor tissue expression of OPN, survivin, p53 and cyclin D1 may serve as markers to predict response to naCHT in pediatric advanced MPNST. Future studies in more numerous group of patients are needed to confirm these preliminary results.

show abstract

Osteopontin: Its Potential Role in Cancer of Children and Young Adults

Cited by 18 publications

References 98 publications

Osteopontin at the Crossroads of Inflammation and Tumor Progression

Osteopontin at the Crossroads of Inflammation and Tumor Progression

Plasma levels of osteopontin from birth to adulthood

Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor

Contact Info

Product

Resources

About